IRIS
VIOLA, Anna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.542
NA - Nord America 2.517
AS - Asia 1.374
SA - Sud America 401
Continente sconosciuto - Info sul continente non disponibili 194
AF - Africa 48
OC - Oceania 3
Totale 7.079
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.400
RU - Federazione Russa 1.463
SG - Singapore 627
BR - Brasile 330
CN - Cina 308
IT - Italia 282
IE - Irlanda 243
SE - Svezia 193
HK - Hong Kong 182
FR - Francia 81
VN - Vietnam 79
DE - Germania 78
GB - Regno Unito 52
CA - Canada 47
IN - India 43
PL - Polonia 29
FI - Finlandia 26
BD - Bangladesh 25
AR - Argentina 22
AT - Austria 22
NL - Olanda 20
MX - Messico 19
JP - Giappone 15
EC - Ecuador 12
ZA - Sudafrica 12
ES - Italia 11
NI - Nicaragua 11
ID - Indonesia 10
CL - Cile 9
CO - Colombia 9
PK - Pakistan 9
TR - Turchia 9
GT - Guatemala 8
IQ - Iraq 8
LT - Lituania 8
VE - Venezuela 8
CR - Costa Rica 7
KE - Kenya 7
MY - Malesia 7
PH - Filippine 7
UZ - Uzbekistan 7
HN - Honduras 6
JO - Giordania 6
BE - Belgio 5
JM - Giamaica 5
MA - Marocco 5
PY - Paraguay 5
SA - Arabia Saudita 5
SC - Seychelles 5
CZ - Repubblica Ceca 4
EE - Estonia 4
KZ - Kazakistan 4
NO - Norvegia 4
PE - Perù 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
AO - Angola 3
CH - Svizzera 3
CW - ???statistics.table.value.countryCode.CW??? 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
ET - Etiopia 3
IL - Israele 3
NP - Nepal 3
SV - El Salvador 3
TT - Trinidad e Tobago 3
UA - Ucraina 3
AL - Albania 2
AZ - Azerbaigian 2
BY - Bielorussia 2
GE - Georgia 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
RO - Romania 2
RS - Serbia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
UY - Uruguay 2
AU - Australia 1
BB - Barbados 1
BG - Bulgaria 1
BS - Bahamas 1
BW - Botswana 1
EG - Egitto 1
EU - Europa 1
GD - Grenada 1
GP - Guadalupe 1
GR - Grecia 1
HU - Ungheria 1
IR - Iran 1
KW - Kuwait 1
LK - Sri Lanka 1
LY - Libia 1
MM - Myanmar 1
PA - Panama 1
RE - Reunion 1
TH - Thailandia 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.890
Salva come PNG Salva come JPEG
Città #
Moscow 450
Ashburn 430
Singapore 315
San Jose 249
Dublin 241
Hong Kong 182
Chandler 169
Dallas 141
Nyköping 94
Council Bluffs 82
Beijing 81
Messina 61
Los Angeles 59
Lauterbourg 39
Santa Clara 38
The Dalles 38
Princeton 37
Medford 33
Munich 31
New York 29
São Paulo 28
Hanoi 25
Des Moines 24
Ho Chi Minh City 22
Orem 22
Frankfurt am Main 20
Redondo Beach 20
Buffalo 19
Chennai 18
Catania 17
Rome 17
Atlanta 16
Brooklyn 16
Milan 15
Seattle 15
Vienna 15
London 14
Tokyo 14
Ann Arbor 13
Denver 13
Phoenix 12
Warsaw 12
Amsterdam 11
Lawrenceville 11
Stockholm 11
Guangzhou 10
Managua 10
Mexico City 10
Montreal 10
Nuremberg 10
Jacksonville 9
Jinan 9
Lappeenranta 9
San Francisco 9
Curitiba 8
North Bergen 8
Rio de Janeiro 8
Shanghai 8
Tianjin 8
Wilmington 8
Chicago 7
Columbus 7
Dearborn 7
Houston 7
Johannesburg 7
Manchester 7
Porto Alegre 7
San José 7
Toronto 7
Turin 7
Turku 7
Amman 6
Boston 6
Campinas 6
Changsha 6
Guatemala City 6
Lahore 6
Mumbai 6
Nairobi 6
Nanjing 6
Pozzuolo Martesana 6
Shenzhen 6
Tashkent 6
Belo Horizonte 5
Brasília 5
Brussels 5
Düsseldorf 5
Hebei 5
Helsinki 5
Jakarta 5
Kuala Lumpur 5
Palermo 5
Randolph Township 5
Secaucus 5
Zhengzhou 5
Baghdad 4
Bremen 4
Cagliari 4
Guayaquil 4
Haikou 4
Totale 3.582
Salva come PNG Salva come JPEG
Nome #
Corticosteroid use in patients with inflammatory bowel diseases: A real-life sub-analysis of the Italian DICE study 289
Diagnostic accuracy of faecal calprotectin in a symptom-based algorithm for early diagnosis of inflammatory bowel disease adjusting for differential verification bias using a Bayesian approach 230
Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project 190
Cancer risk in inflammatory bowel disease: a 6-year prospective multicenter nested case-control IG-IBD study 185
DWI ratios: New indexes for Crohn's disease activity at magnetic resonance enterography? 166
Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab 166
Direct oral anticoagulants increase the risk of anaemia and hospitalization in IBD patients with active intestinal disease 166
Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study 162
Effectiveness of Ustekinumab on Crohn‘s Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD) 162
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis 161
Role of IL-33/ST2 Pathway in Inflammatory Bowel Disease: An Overview and Future Perspectives 156
Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study 156
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 155
Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD “AGED study” 152
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study 149
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: The IG-IBD LIVE study 138
Quality of Life (QoL) in Patients with Chronic Inflammatory Bowel Diseases: How Much Better with Biological Drugs? 133
A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease 129
Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study 128
Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study 127
Inflammatory Bowel Disease in the Elderly – Knowledge Gaps and Potential Directions in Research 125
A real world investigation on prevalence, clinical features, and therapy of inflammatory bowel disease in the city of Messina, Italy 122
Tissue levels of Tumour Necrosis Factor-alpha as molecular biomarker of inflammation and prediction of sustained treatment response in patients with Ulcerative Colitis. 122
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches 118
Management of patients with inflammatory bowel disease and outcomes during the first wave of the Covid-19 pandemic 115
Defense mechanisms and inflammatory bowel diseases: a narrative review 111
Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases 111
Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy 110
Efficacy and Safety of Biological Therapies and JAK Inhibitors in Older Patients with Inflammatory Bowel Disease 107
Stevens-Johnson syndrome on treatment with sulfasalazine for Crohn’s disease: Need for a multidisciplinary approach 106
Genetic Polymorphisms on TNFA, TNFRSF1A, and TNFRSF1B Genes Predict the Effectiveness of Anti-TNF-α Treatment in Inflammatory Bowel Disease Patients 103
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar 102
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy 102
Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study 101
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 100
Objective comparison of vedolizumab and ustekinumab effectiveness in Crohn's disease patients failure to TNF-alpha inhibitors 99
IL PAZIENTE ANZIANO CON MALATTIA INFIAMMATORIA CRONICA INTESTINALE: OSSERVAZIONI IN UN GRUPPO DI PAZIENTI AMBULATORIALI 99
DWI ratios at MR-Enterography: a new way for inflammation degree assessment in Crohn's disease patients? 98
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results from the SoCOVID-19 Survey 97
Ultrasonography tight control and monitoring in crohn's disease during different biological therapies: a multicenter study 94
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD) 93
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study 92
Portal hypertensive enteropathy: multimodality assessment through computed tomography and magnetic resonance enterography 90
Predictors of Covid-19 vaccination acceptance in IBD patients: a prospective study 87
Mitigating the Risk of Tofacitinib-induced Adverse Events in the Elderly Population with Ulcerative Colitis 84
Low Adherence is Associated with Chronic Active Disease in Ulcerative Colitis: A Retrospective Study from a Single Referral Center 83
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study 77
Upadacitinib-Induced Hemolysis in a Patient With Glucose-6-Phosphate Dehydrogenase Deficiency-A Possible Adverse Drug Reaction 76
Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD) 75
Epidemiology and clinical course of late onset inflammatory bowel disease 73
Incident Colorectal Cancer in Inflammatory Bowel Disease 68
SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501 67
Ménétrier's disease in a patient with refractory ulcerative colitis: a clinical challenge and review of the literature 60
Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease 56
Cardiovascular Risk Assessments and Ultrasound-Assisted Re-Stratification in Patients with Inflammatory Bowel Disease (IBD) 51
Letter: the clinical course of Crohn's disease—the Sicilian experience 50
Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study 48
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease 42
Ulcerative Colitis in Adulthood and in Older Patients: Same Disease, Same Outcome, Same Risks? 42
TNF-α Quantification in Formalin-Fixed Paraffin-Embedded Tissues as a Predictive Biomarker in Ulcerative Colitis 42
Standard Therapeutic Approach and New Therapies 40
null 40
Psychological impairment in inflammatory bowel diseases: the key role of coping and defense mechanisms 38
Suboptimal disease control and contributing factors in Italian IBD patients: The IBD-PODCAST Study 35
null 33
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19 30
The Effectiveness of Risankizumab as Induction Therapy for Crohn's Disease: Data From the Sicilian Network for Inflammatory Bowel Diseases 28
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE study 20
Managing Acute Severe Ulcerative Colitis in the Older Patient: A Growing Concern 17
Totale 7.079
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.432
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.432
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022246 0 0 0 0 8 4 14 10 11 74 21 104
2022/2023597 39 65 26 53 29 45 14 28 268 11 13 6
2023/2024256 20 29 36 54 14 23 7 15 0 33 8 17
2024/20251.244 16 21 16 79 60 76 94 194 271 79 133 205
2025/20263.574 156 145 216 227 339 745 474 490 437 188 65 92
2026/2027902 77 358 175 252 40 0 0 0 0 0 0 0
Totale 7.079